Preloading Magnesium Attenuate Cisplatin-induced Nephrotoxicity

• Status: Completed
• Trial end date: 2016-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether magnesium preloading reduce incident of cisplatin induced acute kidney injury in head and neck cancer who receiving low dose cisplatin (40 mg/m2 weekly for 7 weeks).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mahidol University
• Treatments: Cisplatin

Criteria

Inclusion Criteria:

• Age > 18 years

• Eastern Cooperative Oncology Group score 0-2

• First Diagnosed Head and neck cancer and plan for treatment with cisplatin

• Serum creatinine ≤1.5 mg/dl or eGFR≥60(ml/min/1.73 m2)

Exclusion Criteria:

• Prior treatment with cisplatin before randomization

• Uncontrolled concurrent disease

• Pregnancy